Recurrent venous thromboembolism after discontinuation of rivaroxaban therapy in a patient with antiphospholipid syndrome. Issue 1 (10th January 2019)

• Record Type: Journal Article
• Authors: Yagi, Shusuke; Nishiyama, Seiichi; Abe, Toshio; Sata, Masataka
• Is Part Of: BMJ case reports. Volume 12:Issue 1(2019)
• Publication Date: 2019-01-10
• Subjects: cardiovascular medicine -- venous thromboembolism; Medicine -- Case studies -- Periodicals; 610.5
• DOI: 10.1136/bcr-2018-227663
• Languages: English
• ISSNs: 1757-790X

Abstract

Abstract : Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterised by thromboembolic events including venous thromboembolism (VTE) in association with the presence of antiphospholipid antibodies. The standard treatment of VTE historically consists of anticoagulation therapy with warfarin, a vitamin K antagonist. Recently, direct oral anticoagulants, including rivaroxaban have become available for the treatment of VTE. However, the choice of anticoagulant, and the duration of anticoagulation in patients with APS has not been determined yet due to lack of evidence. Here, we report a case of recurrent venous thrombosis after discontinuation of rivaroxaban therapy and avoiding sedentary lifestyle in a patient with APS. We suggest that indefinite anticoagulation therapy might be needed even in low-risk APS cases.